These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24737911)

  • 21. Effects of TNF-α inhibitors on abdominal adiposity in patients with inflammatory rheumatic diseases.
    Toussirot É; Dumoulin G
    J Rheumatol; 2014 Dec; 41(12):2491. PubMed ID: 25452185
    [No Abstract]   [Full Text] [Related]  

  • 22. Insights into uveitis in association with spondyloarthritis from a large patient survey.
    Keck KM; Choi D; Savage LM; Rosenbaum JT
    J Clin Rheumatol; 2014 Apr; 20(3):141-5. PubMed ID: 24662555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome.
    Lee CG; Lee JK; Kang YS; Shin S; Kim JH; Lim YJ; Koh MS; Lee JH; Kang HW
    Am J Gastroenterol; 2015 Feb; 110(2):310-9. PubMed ID: 25583325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of radiographic progression at two years in a cohort of patients with non-radiographic axial spondyloarthritis treated with TNF-α blockers.
    Almirall M; López-Velandia JG; Maymó J
    Reumatol Clin; 2014; 10(2):134-5. PubMed ID: 23827199
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer.
    Zilli T; Chagnon M; Van Nguyen T; Bahary JP; Guay JP; Dufresne A; Taussky D
    Cancer; 2010 Dec; 116(24):5650-8. PubMed ID: 20737574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation.
    Pedersen SJ; Chiowchanwisawakit P; Lambert RG; Østergaard M; Maksymowych WP
    J Rheumatol; 2011 Jul; 38(7):1349-54. PubMed ID: 21459937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.
    Toussirot É; Mourot L; Dehecq B; Wendling D; Grandclément É; Dumoulin G;
    Eur J Nutr; 2014 Apr; 53(3):951-61. PubMed ID: 24173963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of waist circumference with body mass index for predicting abdominal adipose tissue.
    Oka R; Miura K; Sakurai M; Nakamura K; Yagi K; Miyamoto S; Moriuchi T; Mabuchi H; Yamagishi M; Takeda Y; Hifumi S; Inazu A; Nohara A; Kawashiri MA; Kobayashi J
    Diabetes Res Clin Pract; 2009 Jan; 83(1):100-5. PubMed ID: 19019478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    J Rheumatol; 2004 Mar; 31(3):531-8. PubMed ID: 14994401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
    Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
    J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.
    Kang KY; Ju JH; Park SH; Kim HY
    Rheumatology (Oxford); 2013 Apr; 52(4):718-26. PubMed ID: 23275389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.